Four years of multi-billion dollar Google tears blood glucose monitoring final dream
Recently, Verily, a life sciences organization of Google's parent company Alphabet, announced that it will officially terminate the "smart contact lens" project for tear blood glucose monitoring for four years.
According to reports, the project originally planned to use micro-sensors embedded in contact lenses to help diabetic patients detect blood sugar levels in tears in real time, instead of the commonly used poke finger detection methods. However, in the announcement last Friday, the company said: "Although after four years of research, tear blood sugar level testing is indeed a huge project. Both technically and scientifically, there are insurmountable gaps. â€
"According to our previous clinical studies on contact lens blood glucose sensing, the link between tear blood glucose levels and human blood glucose levels is not very close and does not fully meet the requirements of relevant medical devices ."
At the beginning of its birth, Verily was not called Verily, it was just Google's life sciences department. Although it has cooperated with Alcon, an eye care company of Novartis, a well-known medical and health company in Switzerland, it has been questioned by many people because of the lack of progress in recent years.
Of course, in the company's words, the contact lens project has completed many successful experiments in a controlled environment. However, the live test in the real environment has not been carried out because the internal environment of the eye is always changing, which is beyond the control of the R&D team.
Although this project has taken many years and cost billions of dollars, companies in the technology industry or life sciences industry have indeed failed to achieve any key breakthroughs. There is even a book dedicated to the failures that have occurred.
But despite this, technology companies such as Google and Apple are very interested in non-invasive blood glucose level testing research, and believe that this piece of innovation will benefit millions of people. After all, according to the US Centers for Disease Control and Prevention, the number of people with diabetes and potential diabetes in a country alone exceeds 100 million. Even some people have to be poked several times a day in order to detect blood sugar levels.
In the announcement, Verily said: "The company will continue to work with other life science partners in the future to focus on diabetes research projects. To further support diabetes management, we will continue to focus on innovative non-invasive blood glucose level testing research to improve diabetes patients. At this stage, we work closely with dynamic blood glucose meter manufacturing company Dexcom to develop a small, sustainable blood glucose tester. At the same time, we also teamed up with Sanofi to form a joint venture company, Onduo, hoping to bring it to patients with type 2 diabetes. More treatment of the gospel."
Finally, the company said that the termination of the contact lens project is not a loss, and will use more development opportunities in the future to develop new products for ophthalmic health, such as the development of smart contact lenses for elderly hyperopia and vision recovery after cataract surgery.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.apipepdites.com